Cellectis (NASDAQ: CLLS) and Incyte Corporation (NASDAQ:INCY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Valuation & Earnings

This table compares Cellectis and Incyte Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cellectis $49.49 million 22.02 -$78.63 million ($2.08) -14.61
Incyte Corporation $1.31 billion 17.93 $9.84 million ($0.78) -146.40

Incyte Corporation has higher revenue and earnings than Cellectis. Incyte Corporation is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.


This table compares Cellectis and Incyte Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellectis -164.32% -26.70% -22.02%
Incyte Corporation -11.77% -21.57% -9.33%

Volatility and Risk

Cellectis has a beta of 2.29, suggesting that its stock price is 129% more volatile than the S&P 500. Comparatively, Incyte Corporation has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cellectis and Incyte Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis 0 1 6 0 2.86
Incyte Corporation 0 4 18 0 2.82

Cellectis currently has a consensus target price of $40.00, indicating a potential upside of 31.62%. Incyte Corporation has a consensus target price of $144.75, indicating a potential upside of 26.76%. Given Cellectis’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cellectis is more favorable than Incyte Corporation.

Insider & Institutional Ownership

14.8% of Cellectis shares are held by institutional investors. Comparatively, 88.9% of Incyte Corporation shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 17.7% of Incyte Corporation shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Incyte Corporation beats Cellectis on 9 of the 13 factors compared between the two stocks.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.